Paul Richardson

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint New treatments for multiple myeloma
    Paul G Richardson
    Harvard Medical School, Boston, Massachusetts, USA
    Oncology (Williston Park) 19:1781-92; discussion 1792, 1795-7. 2005
  2. doi request reprint Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
    Paul Richardson
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 153:212-21. 2011
  3. doi request reprint Management of treatment-emergent peripheral neuropathy in multiple myeloma
    P G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 26:595-608. 2012
  4. doi request reprint Pomalidomide: new immunomodulatory agent with potent antiproliferative effects
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Crit Rev Oncol Hematol 88:S36-44. 2013
  5. doi request reprint Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Leuk Res 37:829-37. 2013
  6. doi request reprint Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
    Paul G Richardson
    Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 121:1961-7. 2013
  7. doi request reprint Drug safety evaluation of defibrotide
    Paul G Richardson
    Dana Farber Cancer Institute, Medical Oncology, 450 Brookline Avenue, Mayer 232, Boston 02215, USA
    Expert Opin Drug Saf 12:123-36. 2013
  8. doi request reprint The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib
    Paul G Richardson
    Dana Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA
    Eur J Haematol 88:446-9. 2012
  9. ncbi request reprint An update of novel therapeutic approaches for multiple myeloma
    Paul Richardson
    Dana Farber Cancer Institute, D1B02, 44 Binney Street, Boston, MA 02115, USA
    Curr Treat Options Oncol 5:227-38. 2004
  10. ncbi request reprint Bortezomib: proteasome inhibition as an effective anticancer therapy
    Paul G Richardson
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Dana 1B02, Boston, MA 02115, USA
    Future Oncol 1:161-71. 2005

Research Grants

Detail Information

Publications172 found, 100 shown here

  1. ncbi request reprint New treatments for multiple myeloma
    Paul G Richardson
    Harvard Medical School, Boston, Massachusetts, USA
    Oncology (Williston Park) 19:1781-92; discussion 1792, 1795-7. 2005
    ....
  2. doi request reprint Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
    Paul Richardson
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 153:212-21. 2011
    ..Concomitant ESA use with VMP/MP in previously untreated MM patients did not adversely affect TTP or OS, or increase thromboembolic risk. However, RBC transfusion was associated with significantly shorter survival...
  3. doi request reprint Management of treatment-emergent peripheral neuropathy in multiple myeloma
    P G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 26:595-608. 2012
    ..Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions...
  4. doi request reprint Pomalidomide: new immunomodulatory agent with potent antiproliferative effects
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Crit Rev Oncol Hematol 88:S36-44. 2013
    ..Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM...
  5. doi request reprint Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Leuk Res 37:829-37. 2013
    ..This mini-review highlights the role of protein acetylation in the development of cancers and the rationale for the use of HDAC inhibitors in this patient population...
  6. doi request reprint Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
    Paul G Richardson
    Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 121:1961-7. 2013
    ..This study is registered at http://www.clinicaltrials.gov as #NCT00833833...
  7. doi request reprint Drug safety evaluation of defibrotide
    Paul G Richardson
    Dana Farber Cancer Institute, Medical Oncology, 450 Brookline Avenue, Mayer 232, Boston 02215, USA
    Expert Opin Drug Saf 12:123-36. 2013
    ..None of the articles, to date, provide a comprehensive review of the safety of DF in VOD and/or a range of other conditions...
  8. doi request reprint The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib
    Paul G Richardson
    Dana Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA
    Eur J Haematol 88:446-9. 2012
    ..This case further supports that combination treatment with lenalidomide and bortezomib is an effective therapy in the management of patients with relapsed and refractory MM...
  9. ncbi request reprint An update of novel therapeutic approaches for multiple myeloma
    Paul Richardson
    Dana Farber Cancer Institute, D1B02, 44 Binney Street, Boston, MA 02115, USA
    Curr Treat Options Oncol 5:227-38. 2004
    ..Clinical trials are confirming the remarkable activity and improved tolerability of some of the new agents identified through this paradigm, providing exciting evidence of translational success in MM...
  10. ncbi request reprint Bortezomib: proteasome inhibition as an effective anticancer therapy
    Paul G Richardson
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Dana 1B02, Boston, MA 02115, USA
    Future Oncol 1:161-71. 2005
    ..Clinical development is ongoing to investigate its activity as monotherapy and in combination regimens for the treatment of non-Hodgkin's lymphoma, solid tumors, and early presentations of myeloma...
  11. ncbi request reprint Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    Paul G Richardson
    Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 24:3113-20. 2006
    ..To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma...
  12. ncbi request reprint A review of the proteasome inhibitor bortezomib in multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Division of Hematologic Oncology, Dana 1B02, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Pharmacother 5:1321-31. 2004
    ..Its use in earlier-stage MM, other haematological malignancies and in solid tumours as monotherapy and in combination therapy is currently under investigation...
  13. pmc A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3458-64. 2006
    ..Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone...
  14. ncbi request reprint Lenalidomide in multiple myeloma
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Divison of Hematologic Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 6:1165-73. 2006
    ..This review summarizes the profile of lenalidomide and the current evidence for its efficacy in multiple myeloma...
  15. ncbi request reprint Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 18:598-608. 2006
    ..This review presents recent data from clinical trials of these combinations and discusses their implications...
  16. ncbi request reprint The emerging role of novel therapies for the treatment of relapsed myeloma
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Natl Compr Canc Netw 5:149-62. 2007
    ..This review focuses on results from key phase II and III trials of bortezomib, thalidomide, and lenalidomide alone or in combination, and their emerging role in improving outcomes...
  17. ncbi request reprint Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
    Paul G Richardson
    Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 137:429-35. 2007
    ..Bortezomib should be considered an appropriate treatment for elderly and high-risk patients with relapsed multiple myeloma...
  18. ncbi request reprint Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
    Paul G Richardson
    Department of Medical Oncology Hematologic Malignancies, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Cancer 106:1316-9. 2006
    ..Bortezomib, a first-in-class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT...
  19. ncbi request reprint Proteasome inhibition in hematologic malignancies
    Paul G Richardson
    Dana Farber Cancer, Institute, Harvard Medical School, Boston, Massachusetts, USA
    Ann Med 36:304-14. 2004
    ..Available data suggest that bortezomib will be useful in the treatment of a variety of hematologic malignancies...
  20. ncbi request reprint Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 352:2487-98. 2005
    ..This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies...
  21. ncbi request reprint Proteasome inhibition in the treatment of cancer
    Paul G Richardson
    Dana Farber Cancer Institute, Department of Adult Oncology, Boston, Massahusetts 02115, USA
    Cell Cycle 4:290-6. 2005
    ..Encouraging activity has been demonstrated with bortezomib in the first-line treatment of myeloma and in patients with mantle cell lymphoma. Investigations of its utility in the treatment of patients with solid tumors are ongoing...
  22. ncbi request reprint Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    Paul Gerard Guy Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    Blood 106:2977-81. 2005
    ..Chromosome 13 deletion and elevated beta2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study...
  23. ncbi request reprint Novel biological therapies for the treatment of multiple myeloma
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Best Pract Res Clin Haematol 18:619-34. 2005
    ....
  24. ncbi request reprint Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:3557-60. 2007
    ..These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy...
  25. ncbi request reprint Emerging trends in the clinical use of bortezomib in multiple myeloma
    Paul G Richardson
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 6:84-8. 2005
    ..The use of bortezomib in MM therapy, including ongoing randomized phase III trials, is reviewed herein...
  26. ncbi request reprint Bortezomib: a novel therapy approved for multiple myeloma
    Paul G Richardson
    Harvard Medical School, Boston, MA, USA
    Clin Adv Hematol Oncol 1:596-600. 2003
    ..Bortezomib was recently approved for the treatment of multiple myeloma. It is currently being investigated, both as a single agent and in combination, in phase I and II trials in a variety of tumor types...
  27. ncbi request reprint Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide
    Paul Richardson
    Jerome Lipper Myeloma Center, Division of Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Hematol 42:S9-15. 2005
    ..Lenalidomide is currently being tested in combination with both standard and novel agents, including bortezomib, for patients with relapsed/refractory multiple myeloma...
  28. ncbi request reprint Bortezomib: proteasome inhibition as an effective anticancer therapy
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Annu Rev Med 57:33-47. 2006
    ..Clinical development is ongoing to investigate its activity as monotherapy and in combination regimens for the treatment of non-Hodgkin's lymphoma, solid tumors, and earlier presentations of myeloma...
  29. ncbi request reprint Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity
    Paul Richardson
    Division of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Mass 02115, USA
    Mayo Clin Proc 79:875-82. 2004
    ....
  30. ncbi request reprint Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers
    Paul G Richardson
    Jerome Lipper Myeloma Center, Division of Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Control 10:361-9. 2003
    ..The novel proteasome inhibitor bortezomib has shown antitumor activity in preclinical studies and has entered clinical trials, with encouraging results to date...
  31. ncbi request reprint New drugs for myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Dana 1B02, Boston, Massachusetts 02115, USA
    Oncologist 12:664-89. 2007
    ..This review therefore focuses on the extensive clinical data available from studies of these drugs in the treatment of newly diagnosed and advanced multiple myeloma...
  32. ncbi request reprint Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia
    Paul G Richardson
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 8:S4-S12. 2010
    ..Regular screening and monitoring, combined with patient education and effective management strategies, can reduce the risk of these treatment-related complications, as well as their consequences...
  33. pmc Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial
    Paul G Richardson
    Department of Adult Oncology, Harvard Medical School, Boston, MA, USA
    Biol Blood Marrow Transplant 16:1005-17. 2010
    ..In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day was selected for ongoing phase III trials in VOD...
  34. ncbi request reprint Tailoring treatment for multiple myeloma patients with relapsed and refractory disease
    Paul G Richardson
    Harvard Medical School, Jerome Lipper Center for Multiple Myeloma, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology (Williston Park) 24:22-9. 2010
    ..Additional clinical challenges discussed in this article are renal dysfunction, extramedullary disease, and advanced bone disease. Finally, participation in clinical trials is especially encouraged in this patient population...
  35. pmc Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 150:428-37. 2010
    ..The study was closed prematurely for resource-based reasons, precluding dose comparison. Nonetheless, antitumour activity was observed, with promising response rates and promising severity of peripheral neuropathy...
  36. ncbi request reprint Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:4337-43. 2002
    ..Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure...
  37. doi request reprint Use of defibrotide in the treatment and prevention of veno-occlusive disease
    Paul Richardson
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Hematol 2:365-76. 2009
    ..In addition, DF may be effective prophylaxis for VOD in high-risk patients. This review will focus on a summary of the pharmacology of DF and the clinical evidence for its use in VOD...
  38. doi request reprint Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 153:729-40. 2011
    ..The results of this study support additional studies of this combination approach in MM...
  39. doi request reprint Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 29:4243-9. 2011
    ..Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory MM...
  40. pmc The Medical Research Council Myeloma IX trial: the impact on treatment paradigms
    Paul G Richardson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Haematol 88:1-7. 2012
    ....
  41. ncbi request reprint Hepatic veno-occlusive disease following hematopoietic stem cell transplantation
    P Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Acta Haematol 106:57-68. 2001
    ..The purpose of this review is to discuss the pathophysiology and clinical features of VOD, and the current status and future directions of research for both prevention and treatment...
  42. ncbi request reprint Thalidomide: emerging role in cancer medicine
    Paul Richardson
    Jerome Lipper Myeloma Center, Division of Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Annu Rev Med 53:629-57. 2002
    ..Activity has also been demonstrated in chronic graft-versus-host disease and in symptom relief as part of palliative care...
  43. pmc Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:5713-9. 2009
    ..This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-tolerated dose (MTD) of lenalidomide plus bortezomib in patients with relapsed or with relapsed and refractory MM...
  44. doi request reprint Bortezomib in the front-line treatment of multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 8:1053-72. 2008
    ....
  45. ncbi request reprint Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD
    Paul Richardson
    Division of Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Pathophysiol Haemost Thromb 33:50-3. 2003
  46. ncbi request reprint A phase 2 study of bortezomib in relapsed, refractory myeloma
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 348:2609-17. 2003
    ..Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity...
  47. doi request reprint Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 144:895-903. 2009
    ..Bortezomib-associated peripheral neuropathy is manageable and reversible in most patients with relapsed myeloma. Dose modification using a specific guideline improves peripheral neuropathy management without adversely affecting outcome...
  48. ncbi request reprint Clinical update: proteasome inhibitors in hematologic malignancies
    Paul Richardson
    Jerome Lipper Multiple Myeloma Center, Division of Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Treat Rev 29:33-9. 2003
    ..Both trials showed responses (including complete responses) with manageable toxicities, forming the basis for an ongoing phase III trial comparing response to bortezomib versus high-dose dexamethasone...
  49. doi request reprint Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Paul Richardson
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 114:772-8. 2009
    ..These data support treatment with single-agent lenalidomide, as well as its use in steroid-sparing combination approaches. The study is registered at http://www.clinicaltrials.gov as NCT00065351...
  50. pmc Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 27:3518-25. 2009
    ..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients...
  51. pmc Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 116:679-86. 2010
    ..Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105...
  52. ncbi request reprint Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment
    Toshiaki Hayashi
    The Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 1:851-60. 2002
    ..These studies provide the rationale for clinical trials of As2O3, either alone or together with dexamethasone, to overcome classical drug resistance and improve outcome in patients with MM...
  53. pmc Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target
    Dharminder Chauhan
    The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 16:309-23. 2009
    ..Our study therefore validates targeting pDC-MM interactions as a therapeutic strategy to overcome drug resistance in MM...
  54. ncbi request reprint Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
    Dharminder Chauhan
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02215, USA
    Blood 104:2458-66. 2004
    ..Together, these preclinical studies suggest that combining bortezomib with PK may enhance its clinical efficacy, reduce attendant toxicity, and overcome conventional and bortezomib resistance in patients with relapsed refractory MM...
  55. pmc Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity
    Antonia Cagnetta
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 122:1243-55. 2013
    ....
  56. pmc Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:1656-63. 2007
    ..Taken together, these results show that AZD6244 targets both MM cells and OCs in the BM microenvironment, providing the preclinical framework for clinical trials to improve patient outcome in MM...
  57. ncbi request reprint The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
    Dharminder Chauhan
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 103:3158-66. 2004
    ..Together, these findings provide the framework for clinical evaluation of CDDO-Im, either alone or in combination with bortezomib, to overcome drug resistance and improve patient outcome in MM...
  58. ncbi request reprint The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 1:539-44. 2002
    ....
  59. pmc A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
    Gullu Gorgun
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 115:5202-13. 2010
    ..MLN8237 is currently in phase 1 and phase 2 clinical trials in patients with advanced malignancies, and our preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM...
  60. ncbi request reprint Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, The Department of Medical Oncology, Cancer Biology, Boston Veteran Affairs Healthcare System, Boston, MA, USA
    Blood 101:3606-14. 2003
    ..These studies may therefore allow improved therapeutic use of 2ME2, based upon targeting genes that regulate MM cell growth and survival...
  61. ncbi request reprint MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 12:5887-94. 2006
    ..The purpose of this study is to delineate the biological significance of IkappaB kinase (IKK) beta inhibition in multiple myeloma cells in the context of bone marrow stromal cells (BMSC) using a novel IKKbeta inhibitor MLN120B...
  62. ncbi request reprint Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:2846-52. 2004
    ..1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of SGN-40 as a potential new therapy to improve patient outcome in MM...
  63. pmc PI3K/p110{delta} is a novel therapeutic target in multiple myeloma
    Hiroshi Ikeda
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    Blood 116:1460-8. 2010
    ..Our studies therefore show that PI3K/p110delta is a novel therapeutic target in MM and provide the basis for clinical evaluation of CAL-101 to improve patient outcome in MM...
  64. ncbi request reprint Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment
    Toshiaki Hayashi
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:7540-6. 2004
    ....
  65. ncbi request reprint A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 8:407-19. 2005
    ..Combining NPI-0052 and Bortezomib induces synergistic anti-MM activity. Our study therefore provides the rationale for clinical protocols evaluating NPI-0052, alone and together with Bortezomib, to improve patient outcome in MM...
  66. ncbi request reprint A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:8350-8. 2005
    ....
  67. pmc Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma
    Dharminder Chauhan
    The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 111:1654-64. 2008
    ..Taken together, our study provides the preclinical rationale for clinical protocols evaluating bortezomib together with NPI-0052 to improve patient outcome in MM...
  68. ncbi request reprint Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:11712-20. 2005
    ....
  69. ncbi request reprint Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 64:8746-53. 2004
    ..These findings have clinical significance, because identification of downstream apoptotic signaling after topoisomerase I inhibition will both elucidate mechanisms of resistance and optimize future combination chemotherapy against MM...
  70. ncbi request reprint NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 102:2615-22. 2003
    ..Finally, a study using NVP-LAQ824 in a preclinical murine myeloma model provides in vivo relevance to our in vitro studies. Taken together, these findings provide the framework for NVP-LAQ824 as a novel therapeutic in MM...
  71. ncbi request reprint Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:5898-906. 2005
    ..These results provide the preclinical rationale for clinical trials of CHIR-12.12 to improve patient outcome in multiple myeloma...
  72. ncbi request reprint Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
    Toshiaki Hayashi
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 128:192-203. 2005
    ..These studies defined the mechanisms whereby IMiDs trigger NK cell-mediated tumour-cell lysis, further supporting their therapeutic use in MM...
  73. ncbi request reprint Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:1346-58. 2002
    ..These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival...
  74. ncbi request reprint Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 100:3063-7. 2002
    ..Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease...
  75. ncbi request reprint BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 136:414-23. 2007
    ....
  76. ncbi request reprint NF-kappa B as a therapeutic target in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:16639-47. 2002
    ..Furthermore, they provide the framework for clinical evaluation of novel MM therapies based upon targeting NF-kappaB...
  77. ncbi request reprint Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 101:1530-4. 2003
    ..Inhibition of JNK activity abrogates PS-341-induced MM cell death. These studies identify molecular targets of PS-341 and provide the rationale for the development of second-generation, more targeted therapies...
  78. pmc Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:14374-9. 2002
    ..These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM...
  79. ncbi request reprint The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2377-80. 2003
    ..These studies, therefore, provide the framework for clinical use of this agent in combination with conventional chemotherapy...
  80. doi request reprint Multiple myeloma
    Marc S Raab
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Lancet 374:324-39. 2009
    ..This treatment framework promises to improve outcome not only for patients with multiple myeloma, but also with other haematological malignancies and solid tumours...
  81. pmc Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
    Makoto Hamasaki
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 105:4470-6. 2005
    ..These results, therefore, show that azaspirane both induces MM cell apoptosis and inhibits cytokine secretion in the BM milieu, providing the framework for clinical trials to improve patient outcome in MM...
  82. pmc Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
    Kihyun Kim
    Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 149:537-49. 2010
    ..Our results therefore support clinical evaluation of AS703026, alone or in combination with other anti-MM agents, to improve patient outcome...
  83. ncbi request reprint Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 63:8428-36. 2003
    ..Our data therefore demonstrate for the first time that inhibiting LPAAT-beta induces cytotoxicity in MM cells in the bone marrow milieu, providing the framework for clinical trials of these novel agents in MM...
  84. pmc Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:1046-52. 2009
    ..Moreover, IKKbeta inhibitors enhanced bortezomib-induced cytotoxicity. Our studies therefore suggest that bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-kappaB activity in MM cells...
  85. ncbi request reprint Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 24:3121-9. 2005
    ..Our studies therefore demonstrate that LPAAT-beta inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clinical PS-341 resistance and improve patient outcome...
  86. ncbi request reprint Proteasome inhibitor therapy in multiple myeloma
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 4:686-92. 2005
    ....
  87. ncbi request reprint Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 63:5850-8. 2003
    ..Moreover, they define the functional association of IGF-IR and beta1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM...
  88. ncbi request reprint FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:7478-84. 2005
    ..These results suggest that FTY720 overcomes drug resistance in multiple myeloma cells and provide the rationale for its clinical evaluation to improve patient outcome in multiple myeloma...
  89. ncbi request reprint Novel biologically based therapies for Waldenstrom's macroglobulinemia
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:309-12. 2003
    ..These molecular studies provide a framework for rational design of the next generation of combination therapies for WM...
  90. pmc Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 109:1220-7. 2007
    ..Our study therefore provides the rationale for clinical protocols evaluating LBW242, alone and together with other anti-MM agents, to improve patient outcome in MM...
  91. pmc Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis
    Kenji Ishitsuka
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1794-800. 2005
    ..Taken together, our results provide the preclinical rationale for clinical protocols of HNK to improve patient outcome in MM...
  92. ncbi request reprint Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
    Noopur Raje
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, VA Boston Healthcare System and Harvard Medical School, Boston, MA 02115, USA
    Blood 104:4188-93. 2004
    ..These studies, therefore, provide the framework for clinical evaluation of mTOR inhibitors combined with IMiDs to improve patient outcome in MM...
  93. doi request reprint The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
    Hiroshi Ikeda
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:4028-37. 2009
    ..We investigated the antitumor effect of murine/human chimeric CD138-specific monoclonal antibody nBT062 conjugated with highly cytotoxic maytansinoid derivatives against multiple myeloma (MM) cells in vitro and in vivo...
  94. doi request reprint Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 69:5835-42. 2009
    ..g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti-MM agents showed lack of antagonism. These results indicate that BEZ235 merits clinical testing, alone and in combination with other agents, in MM...
  95. ncbi request reprint Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
    Richard LeBlanc
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:4996-5000. 2002
    ....
  96. ncbi request reprint The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Boris Lin
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:5019-26. 2002
    ..The demonstrated anti-MM activity of PTK787, coupled with its antiangiogenic effects, provides the framework for clinical trials of this agent to overcome drug resistance and improve outcome in MM...
  97. pmc In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
    Joseph M Negri
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 147:672-6. 2009
    ..Combinations with dexamethasone (Dex), doxorubicin (Doxo) and bortezomib showed no antagonism. Our study highlights the potential role of the tumour microenvironment in modulating the activity of this drug class...
  98. ncbi request reprint Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 101:703-5. 2003
    ..These studies therefore identify p38 MAPK as a novel therapeutic target to overcome drug resistance and improve patient outcome in MM...
  99. ncbi request reprint 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
    Dharminder Chauhan
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02215, USA
    Blood 100:2187-94. 2002
    ..They provide a framework for the use of 2ME2, either alone or in combination with Dex, to overcome drug resistance and to improve outcome in MM...
  100. ncbi request reprint Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib
    Klaus Podar
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:7500-6. 2004
    ....
  101. doi request reprint Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 143:511-9. 2008
    ..These results show that bortezomib was associated with significantly better multidimensional HRQL compared with dexamethasone, consistent with the better clinical outcomes seen with bortezomib...

Research Grants2

  1. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
    ..Abstract Not Provided ..